<DOC>
	<DOCNO>NCT02131337</DOCNO>
	<brief_summary>EFFICAS II propose test hypothesis treatment efficacy correlate contact force parameter apply pulmonary vein isolation ( PVI ) AF ablation .</brief_summary>
	<brief_title>TactiCathÂ® Prospective Effectiveness Pilot Study</brief_title>
	<detailed_description>EFFICAS II single-arm , prospective study , operator access contact force information use actively optimize ablation result adapt power necessary . The endpoint correlate contact force parameter initially apply PV 3 month PV isolation status , compare result EFFICAS I .</detailed_description>
	<mesh_term>Atrial Fibrillation</mesh_term>
	<criteria>Patient least 18 year age 75 year age Patient least one episode sustain ( &gt; 30 ) paroxysmal atrial fibrillation document 12lead ECG , holter monitor , transtelephonic event monitor , telemetry strip , Pacemaker respectively implantable cardioverter defibrillator ( ICD ) within 12 month prior enrolment Patient symptomatic paroxysmal atrial fibrillation ( PAF ) refractory intolerant least one Class IIV antiarrhythmic drug Patient willing capable comply study protocol requirement , include specify followup scheme Patient provide write informed consent prior enrolment study Not adhere inclusion criterion Active systemic infection Recent ( within 3 month ) cardiac event include myocardial infarction , acute coronary syndrome , percutaneous coronary intervention ( PCI ) , valve coronary bypass graft surgery Reversible cause Arrhythmia include thyroid disorder , acute alcohol intoxication , recent ( less 3 month ) major surgical procedure Patient leave atrial diameter &gt; 5.0 cm Patient persistent longstanding persistent atrial fibrillation ( AF ) Left ventricular ejection fraction &lt; 35 % New York Heart Association ( NYHA ) class III IV Previous leave atrial heart ablation procedure , either surgical catheter ablation Patient intracardiac mural thrombus ventriculotomy atriotomy Patient moderate severe structural heart disease demonstrate transthoracic transesophageal echocardiogram four chamber heart ( ventricular dysfunction valve disease ) Tricuspid mitral valve replacement repair If female childbearing potential pregnant breastfeeding Patient bleed diathesis suspect procoagulant state Patient contraindication longterm antithromboembolic therapy ( e. g. acetylsalicylic acid , heparin , warfarin ) Presence condition precludes appropriate vascular access Heart disease corrective surgery anticipate within 6 month Renal failure require dialysis Patient know sensitivity contrast medium ( needed procedure ) adequately control premedication ( totally exclude ) Patient anatomic comorbid condition , Investigator 's opinion , could limit patient 's ability participate study comply followup requirement , impact scientific soundness study result Patient currently participate another clinical trial Patient unlikely survive one year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>